Valneva's 52-Week Low Deepens as Legal Troubles Compound Clinical Setback

Valneva shares hit 52-week low after Phase 3 Lyme vaccine trial fails statistical benchmark; legal probe launched, analysts downgrade, but some institutions add positions.

The French biotech group Valneva is navigating one of its most turbulent periods in recent memory, with its share price plumbing a 52-week trough of €2.34 on the Euronext Paris exchange. The stock has surrendered roughly 39% of its value since the start of the year, a decline that accelerated sharply after a pivotal clinical readout failed to meet statistical benchmarks.

A Phase 3 Trial That Worked — But Didn't Pass

At the heart of the selloff lies the VALOR Phase 3 study for VLA15, the Lyme disease vaccine candidate being developed in partnership with Pfizer. The data showed a 73.2% efficacy rate after the fourth dose — a figure that would typically be considered clinically meaningful. Yet the trial missed its primary statistical endpoint because fewer participants than anticipated contracted Lyme borreliosis during the study period. That pushed the lower bound of the confidence interval below the pre-specified threshold of 20%, creating a regulatory headache that has spooked investors.

Valneva and Pfizer nonetheless intend to submit the data to both the FDA and the European Medicines Agency in the second half of 2026, arguing that the totality of clinical evidence — combining strong efficacy with a favourable safety profile — should sway regulators. Whether that argument will hold remains an open question that could define the company's trajectory for years.

Legal Scrutiny Intensifies

The clinical disappointment has drawn unwelcome attention from the legal community. On 26 April, the US law firm Pomerantz LLP announced it was investigating Valneva SE for potential securities fraud and unlawful business practices, following an earlier similar announcement on 16 April. The probe centres on the 23 March disclosure of the VALOR results, when Valneva and Pfizer characterised the data as positive even as the market reacted violently. Valneva's American Depositary Receipts plunged 37% that single day.

Analyst Sentiment Sours

Wall Street has turned increasingly bearish in the wake of the trial setback. Goldman Sachs downgraded the stock from "Neutral" to "Sell" on 22 April, slashing its price target from €3.25 to €2.15. Wall Street Zen followed suit on 25 April with a "Strong Sell" rating. The consensus among analysts has now slipped to "Hold," with price targets trending decisively lower.

Not everyone has thrown in the towel. Guggenheim maintains a price target of $11.00, though it has not revised that figure since the clinical data emerged. The divergence underscores the uncertainty surrounding Valneva's prospects.

Institutional Activity Offers Little Respite

Despite the carnage in the share price, some institutional investors have been adding exposure. China Universal Asset Management and Marex Group have taken new positions, while VSM Wealth Advisory increased its holding by 125%. Collectively, institutional investors and hedge funds now own approximately 11.4% of the outstanding shares. That has done little to stem the tide, however. The stock trades more than 40% below its 200-day moving average, and the annualised 30-day volatility has surged past 108% — a reflection of the extreme uncertainty enveloping the company.

Commercial Setbacks Add to the Gloom

Valneva's troubles are not confined to the pipeline. Earlier this year, the company voluntarily withdrew its Chikungunya vaccine Ixchiq from the US market following safety investigations. That decision, combined with the VLA15 uncertainty, has left investors questioning the near-term commercial outlook.

What to Watch Next

All eyes will be on the first-quarter earnings report due 7 May. The company has guided for full-year 2025 revenue of between €155 million and €170 million, a forecast that already incorporates the phased withdrawal from third-party distribution. Investors will be particularly focused on the cash position — with a market capitalisation of roughly $474 million, the question of how much liquidity remains to fund the regulatory filings later this year is paramount.

On 21 May, Valneva is scheduled to present at the Bernstein European Small & Mid-Cap Conference in Nice. That forum could provide management with an opportunity to articulate a compelling narrative around VLA15's regulatory path — or it could deepen the scepticism that has driven the stock to its current lows.